Study: Reolysin-Paclitaxel Combination Demonstrates Higher Response than Paclitaxel Therapy Alone

DoD Ovarian Cancer Research Program anticipated funding opportunities for FY24

The FY24 Defense Appropriations Act is anticipated to provide funding for the Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.

April 05, 2024

Vol.50 No.14

In Brief

Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight

Shelley Tworoger, an epidemiologist at Moffitt Cancer Center, was named to two roles at OHSU: head of the Division of Oncological Sciences in the School of Medicine, and associate director for population science at the Knight Cancer Institute.

October 27, 2023

Vol.49 No.40

Drugs & Targets

CHMP issues positive opinion for Rubraca as a first-line maintenance treatment for advanced ovarian cancer

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval a Type II variation for Rubraca (rucaparib), as a first-line maintenance treatment for all women with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy.

October 20, 2023

Vol.49 No.39

Clinical Roundup

USC researchers develop blood test with the potential to detect early-stage ovarian cancer

A study on human tissue and plasma led by researchers at USC Norris Comprehensive Cancer Center shows that their newly developed blood test, OvaPrint, may distinguish between cancerous and benign pelvic masses with up to 91% accuracy, surpassing other commercially available tests.

October 13, 2023

Vol.49 No.38

Clinical Roundup

ASCO issues recommendations for assessing ovarian toxicity in cancer clinical trials

The American Society of Clinical Oncology has released a research statement, “Measuring Ovarian Toxicity in Clinical Trials,” outlining new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials.

October 06, 2023

Vol.49 No.37

Clinical Roundup

Elahere demonstrates OS, PFS benefit regardless of prior PARPi exposure or prior lines of therapy in ovarian cancer

Findings from two subset analyses of the phase III MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer demonstrate an overall survival and progression-free survival benefit.

September 29, 2023

Vol.49 No.36

Study: Reolysin-Paclitaxel Combination Demonstrates Higher Response than Paclitaxel Therapy Alone

YOU MAY BE INTERESTED IN

DoD Ovarian Cancer Research Program anticipated funding opportunities for FY24

Shelley Tworoger named head of oncological science, associate director for population science at OHSU Knight

CHMP issues positive opinion for Rubraca as a first-line maintenance treatment for advanced ovarian cancer

USC researchers develop blood test with the potential to detect early-stage ovarian cancer

ASCO issues recommendations for assessing ovarian toxicity in cancer clinical trials

Elahere demonstrates OS, PFS benefit regardless of prior PARPi exposure or prior lines of therapy in ovarian cancer

Renew today!

Subscriber content

Login